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Hemagglutinin (HA), as a major surface antigen of influ-
enza virus, is widely used as a target for production of 
neutralizing antibodies. Monoclonal antibody, mAb6-9-1, 
directed against HA of highly pathogenic avian influenza 
virus A/swan/Poland/305-135V08/2006(H5N1) was puri-
fied from mouse hybridoma cells culture and character-
ized. The antigenic specificity of mAb6-9-1 was verified 
by testing its cross-reactivity with several variants of HA. 
The mimotopes recognized by mAb6-9-1 were selected 
from two types of phage display peptide libraries. The 
comparative structural model of the HA variant used for 
antibody generation was developed to further facilitate 
epitope mapping. Based on the sequences of the affini-
ty- selected polypeptides and the structural model of HA 
the epitope was located to the region near the receptor 
binding site (RBS). Such localization of the epitope rec-
ognized by mAb6-9-1 is in concordance with its moder-
ate hemagglutination inhibiting activity and its antigenic 
specificity. Additionally, total RNA isolated from the hy-
bridoma cell line secreting mAb6-9-1 was used for ob-
taining two variants of cDNA encoding recombinant sin-
gle-chain variable fragment (scFv) antibody. To ensure 
high production level and solubility in bacterial expres-
sion system, the scFv fragments were produced as chi-
meric proteins in fusion with thioredoxin or displayed on 
a phage surface after cloning into the phagemid vector. 
Specificity and affinity of the recombinant soluble and 
phage-bound scFv were assayed by suitable variants of 
ELISA test. The observed differences in specificity were 
discussed.
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INTRODUCTION
Antibodies are used in many research applications, as 
well as in various diagnostic assays and medical treat-
ments. Hybridoma technology enables production of 
huge amounts of monoclonal antibodies (mAb) against 
the target antigen but it is a laborious, time consuming 
and expensive technique. Growing demand for recombi-
nant antibodies and their derivatives prompted the de-
velopment of various expression platforms. Up to date 
many attempts of their production in mammalian cells 
(Ho et al., 2006), insect cells (Choo et al., 2002), plants 
(Dobhal et al., 2013), yeast or bacteria (Rouet et al., 2012) 
have been reported. The derivatives of antibodies such 
as the antigen-binding fragment (Fab) or the single chain 
variable fragment (scFv) are of particular interest. Their 
reduced structures and molecular weights facilitate ex-
pression and purification process. The scFv fragment 
consists of variable regions of heavy (VH) and light (VL) 
chains of immunoglobulin connected by a flexible linker 
(Kalenik et al., 2014). The scFv can be modified by con-
jugation to drugs or toxins and may penetrate the blood 
and tissue more rapidly than a complete antibody (Cao et 
al., 2012a; Oriuchi et al., 2005). Easiness of modification 
gives many possibilities of direct or indirect detection of 
this protein and facilitates manipulations of its activity 
(affinity to antigens). These properties are especially im-
portant for such targets as rapidly evolving surface anti-
gens of influenza virus.
The influenza viruses belong to Orthomyxoviridae fam-
ily. Their genome consists of a single- stranded negative 
sense RNA. Due to the antigenic drift and shift, result-
ing frequently in novel mutants and re-assortants that 
are able to cross the species barriers, the influenza vi-
ruses are still a serious global problem for humans and 
their livestock, especially for poultry and pigs. Highly 
pathogenic avian H5N1 influenza viruses are responsible 
for serious economic losses to the poultry industry and 
have caused numerous threats to public health. Since 
1996 when H5N1 virus was isolated for the first time 
in China it has spread rapidly and continued to evolve, 
which resulted in a periodic emergence of new phyloge-
netic groups in several regions of the world. Currently, 
H5N1 viruses are divided into multiple clades and sub-
clades based on antigenic variation (Smith et al., 2012; 
Smith et al., 2015; Li et al., 2013). Hemagglutinin (HA), 
a strong surface antigen, is synthesized as a precursor, 
HA0 molecule, which is cleaved into two subunits, HA1 
and HA2 (Szewczyk et al., 2014). The HA1 subunit en-
compasses the membrane-distal globular head containing 
the receptor binding site (RBS) and the vestigial esterase 
domain. The HA2 subunit encompasses the stalk region 
(Velkov, 2013). The main functions of HA during virus 
infection are attachment of the virus to the host cell re-
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ceptor and mediation of the fusion of the virus enve-
lope with the endosomal membrane after endocytosis. 
This glycoprotein is a major target for anti-virus antibod-
ies and a subject of high antigenic variability (antigenic 
drift). Identification and characterization of its antigenic 
epitopes is needed for understanding of the molecu-
lar mechanisms of antigenic drift and viral immune es-
cape, which in turn might result in better selection of 
the vaccine strains. The reactivity of selected monoclonal 
antibodies with escape mutants of  H5 HA were inten-
sively studied but the map of H5 antigenic epitopes is 
still incomplete. Most of the characterized mAbs against 
HA from H5N1 virus recognize the epitopes localized in 
the globular head of HA, most of them overlap the RBS 
and are isolate-specific, (e.g. Cao et al., 2012b; Du et al., 
2013; Wu et al., 2014), while antibodies binding to the 
stem region have often a broad activity (Tan et al., 2015; 
Zuo et al., 2015). Extensive review of H5 HA antigenic 
sites was provided by (Velkov et al., 2013) who described 
the anti-HA antibodies divided into 3 groups: (i) RBS 
selective, (ii) non-RBS, membrane-distal globular domain 
selective and (iii) HA2 selective.
The mAb6-9-1 is a monoclonal mouse antibody se-
creted by the hybridoma cell line 6-9-1, which was 
generated by us from immune cells of a mouse im-
munized with the recombinant H5 HA from A/swan/
Poland/305-135V08/2006 (H5N1). We described usage 
of Fab (antigen-binding fragment) fragment of mAb6-
9-1 in electrochemical immunosensor detecting HA 
from H5N1 viruses (Jarocka et al., 2014). It was applied 
for detection of HA (17-530 aa) from A/Bar-headed 
Goose/Qinghai/12/05(H5N1) and HA1 subunit of HA 
from two strains of H5N1 viruses: A/swan/Poland/305-
135V08/2006 and A/Vietnam/1194/2004 (Jarocka et al., 
2014). The strongest binding was observed for the long 
HA from A/Bar-headed Goose/Qinghai/12/05(H5N1) 
with the detection limit of 2.2 pg/mL. The successful 
application of the derivatives of this antibody prompt-
ed us to perform its broaden characterization, especially 
mapping of an epitope recognized by mAb6-9-1 on the 
structural model of the HA from A/swan/Poland/305-
135V08/2006 (H5N1). Moreover, we described cloning, 
expression and characterization of recombinant scFv 
fragments derived from the mAb6-9-1. The specificity of 
two variants (VLVH and VHVL) of scFv produced in 
fusion with thioredoxin were evaluated by indirect and 
sandwich ELISA assays and confirmed with the scFv 
variant produced by the phage display method.
MATERIALS AND METHODS
Hybridoma propagation and monoclonal antibody 
purification. Mouse hybridoma cell line 6-9-1 that se-
creted monoclonal antibody against hemagglutinin from 
A/swan/Poland/305-135V08/2006 (H5N1) was gener-
ated from splenocytes obtained after immunization of 
mice with the recombinant H5 HA. The hybridoma cells 
were maintained in RPMI-1640 medium (20 mM L-glu-
tamine, 10% fetal bovine serum, 5% CO2, 37°C). The 
mAb6-9-1 was purified from culture supernatant using 
protein G (ThermoScientific).
Comparative modeling of HA from A/swan/
Poland/305-135V08/2006 (H5N1). Structures suitable 
for modeling were chosen from a default BLAST search 
against the PDB database (accessed February 5th, 2015), 
with respect to the serotype (H5), X-ray resolution, and 
sequence length. Two structures emerged through these 
criteria: 2ibx (A/Vietnam/1194/2004 (H5N1)) and 2fk0 
(A/Vietnam/1203/2004 (H5N1)), both having over 
90% sequence identity. Preparation of X-ray structures 
was done in Chimera (v1.11) and consisted of deletion 
of non-standard residues and HOH molecules, N- and 
C-terminal fix and incomplete side chains repair. Both 
structures were aligned with MatchMaker (Meng et al., 
2006) and the most similar chains were used as tem-
plates; 2IBX_A, 2IBX_B, 2FK0_K, 2FK0_L. Modeler 
software (Sali & Blundell, 1993) was used throughout 
the modeling process. Ten different models were gen-
erated and manually evaluated with respect to hydrogen 
bond patterns, AA contact and clashes and Ramachan-
dran plot. The best model was subjected to a minimiza-
tion procedure using AMBER force field (ff14SB) and 
a steepest descent procedure to relieve steric hindrances 
(15Å box, TIP3PBOX solvent model and Cl- to neutral-
ize the structure).
Epitopes mapping. Epitope recognition by puri-
fied mAb6-9-1 was determined using two Phage Display 
Peptide Libraries, Ph.D.™-C7C and Ph.D.™-12 (New 
England Biolabs) according to the manufacturer’s pro-
tocol (Ph.D Phage Display Libraries, version 1.2, New 
England Biolabs). Briefly, the 96-well plates (Maxisorb 
Nunc) were coated with purified mAb6-9-1 (7.5 µg/
well) and incubated at 4°C overnight. After washing with 
TBST (TBS + 0.1% Tween-20) and blocking with BSA 
solution (5 µg/ml), the titrated phage peptide library 
(Ph.D.™-C7C or Ph.D.™-12) was added to each well 
(107–108 plaque forming units (pfu) in 100 µl) and in-
cubated for 60 minutes at room temperature. Unbound 
phages were discarded, plates washed 10 times with 
TBST and bound phages were eluted with 0.2 M glycine-
HCl, (pH 2.2), 1 mg/ml BSA. In a parallel experiment 
the OET protein (see below, Antigens and antibodies 
used in ELISA) at concentration 0.8 mg/ml was used 
for phage elution. Eluted phages were amplified and 
taken to the next panning rounds. After three rounds 
of panning several phage clones were randomly select-
ed, subjected to phage ELISA, (performed according to 
the protocol described in Ph.D Phage Display Libraries, 
New England Biolabs) to confirm their binding capac-
ity with mAb6-9-1. DNA isolated from individual phage 
clones was sequenced and amino acid sequence of the 
corresponding peptides determined. The Pepitope server 
(http://pepitope.tau.ac.il/) (Mayrose et al., 2007a) was 
used to map the selected peptides onto the 3D model of 
HA from A/swan/Poland/305-135V08/2006 (H5N1). 
Using the consensus methodology, both PepSurf  (May-
rose et al., 2007b) and Mapitope algorithms (Bublil et al., 
2007) were executed and their results combined into a 
single prediction including only residues predicted to be 
a part of the epitope in both algorithms. Mapping results 
were compared with the surface of the H5 HA structural 
model using UCSF Chimera (v1.11).
Synthesis of the scFv cDNA. Primers. Sequences 
of primers used in the experiment of scFv synthesis and 
cloning are listed in the Supplementary file Table S1 at 
www.actabp.pl.
Synthesis of VH and VL regions. Sequences encod-
ing the variable regions of light (VL) and heavy (VH) 
chains were obtained according to the method and pro-
cedure described by (Ladiges & Osman, 2001). The main 
steps of procedure are described compendiously below. 
Total RNA was isolated from the hybridoma cell line 
6-9-1 using RNeasy Plus Micro Kit according to the 
manufacturer’s instructions (Qiagen). 6.5 µg of isolated 
RNA and oligo (dT)15 primer were used to synthesize 
blunt-ended cDNA using the cDNA Synthesis System 
(Roche). Next, the PCR OG/GO linker was ligated to 
Vol. 64       87Monoclonal antibody against hemagglutinin of influenza virus H5N1
the cDNA by T4 DNA ligase (Invitrogen). The resulting 
cDNA was used to amplify VH and VL fragments using 
Easy-A High-Fidelity PCR Master Mix (Agilent Technol-
ogies) supplemented with the sets of primers, OG and 
IgGkapp or OG and IgG1HC1 for VL and VH synthe-
sis, respectively. IgGkapp primer corresponded to the 
constant region of the light chain CL whereas IgG1HCl 
corresponded to the CH1 gene (sequences are provided 
in Supplementary file 1: Table S1 at www.actabp.pl). The 
PCR products were cloned into the pGEM-T easy vec-
tor (Promega). Several clones were sequenced and  ana-
lyzed using vbase2 on-line program (http://www.vbase2.
org/vbdnaplot.php) to determine sequences of CDRs of 
VH and VL.
Assembling of scFv. Selected functional clones of 
light and heavy chain of mouse IgG were used to syn-
thesize scFv construct. First, to obtain scFv in VH-VL 
orientation the variable fragments of heavy and light 
chains were amplified using two pairs of primers either 
VHNdeF and scFvVHR or scFvVKF and VkNotR. 
Then VH and VL fragments were assembled into scFv 
by overlapping PCR reaction using external primers 
VHNdeF and VkNotR. The same method was applied 
to synthesize scFv in opposite orientation (VL-VH) us-
ing specific primers: NdeVLF, linkVLR and linkVHF, 
VHrevNot. The PCR reactions were performed using 
Pfu Polymerase (Fermentas). Finally, PCR products were 
digested with NdeI and NotI restriction enzymes and li-
gated into the modified pET26b expression vector (No-
vagen) carrying the sequence encoding His- and Strep- 
tags previously cloned by us.
scFv expression in E. coli. The scFv constructs were 
re-cloned from the pET26b into the modified pET201 
vector carrying the sequence encoding thioredoxin 
which resulted in obtaining two recombinant plasmids: 
pET201/TVHVL and pET201/TVLVH that were used 
for scFv overexpression in E. coli Origami (DE3) strain. 
For an efficient production of recombinant TscFvs sev-
eral different conditions of temperature (37°C, 30°C, 
25°C, 20°C), IPTG concentration (10 mM, 1 mM, 
0.1 mM, 0.05 mM, 0.01 mM) and time of induction (be-
tween 1 h–48 h) were tested. The TscFv expressed by 
E. coli were purified on a gravity flow Ni-TED 1000 col-
umn (Marcherey-Nagel) in denaturing conditions accord-
ing to the procedure described in manufacture’s manual 
(Marcherey-Nagel). The first and the second elution frac-
tions were mixed and dialyzed against stepwise decreas-
ing concentration of urea in the range between 6.0–0 M. 
Each step lasted at least 3 hours. Purity of recombinant 
proteins was evaluated with SDS PAGE.
Phage displayed scFv (PhscFv). The cDNA frag-
ment encoding scFv in VL-VH orientation (without 
thioredoxin) was amplified by Easy A polymerase (Easy-
A High-Fidelity PCR Master Mix, Agilent Technologies) 
with the RRPvuF and VHrevNot primers (sequences 
are provided in Supplementary file 1: Table S1 at www.
actabp.pl) using recombinant plasmid pET26b carrying 
scFv cDNA as a template. The obtained PCR prod-
uct was digested with PvuII and NotI and cloned into 
pSEX81 phagemid vector (Progen). Small-Scale Phage 
Rescue was conducted according to the published proto-
col 154.3.4 by (Dorsam et al., 2002) with minor changes 
(first centrifugation was prolonged to 25 min and 5 h 
incubation in 37°C was changed to 18 h in 30°C). The 
obtained phages (PhVLVH) were titrated according to 
the online protocol ‘Helper Phage Production’ (Stocking-
er Lab website:  http://www.oardc.ohio-state.edu/stock-
ingerlab/Protocols/HelperPhage.pdf) and used in Phage 
ELISA. The ELISA was conducted according to (Dor-
sam et al., 2002) with minor modifications. Briefly, Max-
iSorp plates were coated with 500 ng of the antigen and 
incubated overnight at 4°C, washed with PBS, blocked 
(2 h, 2% skim milk in PBS), incubated with 107-108 pfu 
for 2 h, washed and incubated with anti-M13 antibodies 
conjugated with HRP (GE Healthcare).
Sequencing of mAb6-9-1. The amino acid sequence 
of heavy and light chains of mAb6-9-1 was estimated by 
mass spectrometry of trypsin-digested mAb fragments. 
The analysis was performed in Mass Spectrometry Lab 
at the Institute of Biochemistry and Biophysics Polish 
Academy of Sciences, Warsaw.
Hemagglutination inhibition test. HI tests were 
performed as described previously (Stachyra et al., 2014; 
Stachyra et al., 2016) using inactivated viruses as antigens, 
either the highly pathogenic A/Turkey/Poland/35/2007 
(H5N1) (National Veterinary Research Institute, 
Pulawy, Poland) or the low pathogenic A/chicken/Bel-
gium/150/1999 (H5N2) (DG Deventer, Netherlands). 
HI titer was defined as the reciprocal of the highest dilu-
tion of sera that completely inhibited hemagglutination.
Antigens and antibodies used in ELISA. The fol-
lowing antigens corresponding to HA from A/swan/
Poland/305-135V08/2006 (H5N1) were used: (1) HA/
Nde, a short variant containing region of 17-340 aa with 
His-tag at N- terminus produced (in our laboratory) in 
E. coli; (2) OET, a long variant containing region of 17-
530 aa derived from baculovirus system (Oxford Expres-
sion Technologies, UK); The following recombinant HA 
antigens were purchased from Immune Technology Cor-
poration (all of them are 6x His-tagged and derived from 
293 cell culture): Qinghai – 17–530 aa from A/Bar-head-
ed Goose/Qinghai/12/05 (H5N1); Vietnam – 17–530 aa 
from A/VietNam/1203/2004 (H5N1); Anhui – 18–530 
aa from A/Anhui/1/2005 (H5N1); Cambodia – 24–341 
aa from A/Cambodia/R0405050/2007 (H5N1); Hubei 
– 18–530 aa from A/Hubei/1/2010 (H5N1); Germany 
– 17–342 aa from A/Turkey/Germany-MV/R2472/2014 
(H5N8); Wuhan – 17–529 aa from A/Wuhan/359-
95(H3N2); Netherlands – 17–527 aa from A/chicken/
Netherlands/1/03 (H7N7); New Caledonia – 18-530 aa 
from A/New Caledonia/20/99 (H1N1).
Antibodies. IgY 745 – anty-H5 HA (H5N1) poly-
clonal IgY was purified in our laboratory from eggs 
collected from laying hens immunized with DNA vac-
cine based on pCI vector with cloned cDNA sequence 
encoding 1-568 aa of HA from A/swan/Poland/305-
135V08/2006 (H5N1) (Stachyra et al., 2014). IgY was 
purified using Pierce™ Chicken IgY purification kit 
(ThermoFisher). Anti-M13 HRP-conjugated monoclo-
nal antibody (HRP/Anti-M13 Monoclonal Conjugate, 
GE Healthcare); anti-Strep-tag II monoclonal antibody 
(StrepMAB- Classic, IBA, GmbH); anti – chicken IgY 
(Goat anti-Chicken IgY Fc Secondary Antibody, HRP 
conjugate, Thermo Scientific); anti-mouse HRP antibody 
(Anti-Mouse IgG (γ-chain specific) – Peroxidase anti-
body produced in goat, Sigma Aldrich) were purchased 
as indicated.
Indirect and sandwich ELISA. Indirect ELISA. 
The 96-well MaxiSorp plates (Nunc, Denmark) were 
coated overnight at 4°C with 300 ng of the respective 
antigens. Following 4x washing with PBST buffer (0.1 M 
PBS with 0.05% Tween-20) plates were blocked with 2% 
BSA in PBS for 1.5 h. Next, plates were incubated with 
purified antibody (mAb6-9-1 or TscFv) overnight at 4°C 
and after washing incubated (1.5 h, 37°C) with the anti-
strep-tag antibody, washed and incubated (1 h, 37°C) 
with anti-mouse HRP conjugated IgG. In the case of 
mAb6-9-1 the step with anti-strep incubation was omit-
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ted. Following incubation with TMB (3,3’,5,5’ tetrameth-
ylbenzidine, Sigma-Aldrich) absorbance at 450 nm was 
measured. Denatured (reduced) antigens were obtained 
after incubation with 10 mM DTT for 1 h at 37°C ac-
cording to (Wu et al., 2014).
Sandwich ELISA. The same plates as in Indirect 
ELISA were coated with 500 ng of the TscFv. Wash-
ing and blocking conditions were as above. Next, plates 
were incubated with antigens for 1.5 h at room temper-
ature and after washing incubated (1.5 h) with IgY745 
anti- H5 polyclonal IgY at various dilutions in the range 
1:4 000 to 1:16 000, washed again and incubated (45 min, 
room temperature) with HRP-conjugated goat anti-chick-
en IgY Fc (Thermo Scientific) 1:12 000. Following incu-
bation with TMB absorbance at 450 nm was measured.
RESULTS AND DISCUSSION
Prediction of the epitope recognized by mAb6-9-1
In order to facilitate mapping of the antigenic sites 
recognized by mAb 6-9-1 the structural model of the 
HA variant (A/swan/Poland/305-135V08/2006 (H5N1)) 
used for antibody generation was created (Fig. 1a) as de-
scribed in Materials and Methods.
Two commercial phage display peptide libraries were 
used for selection of peptides that were reactive against 
mAb6-9-1. In both of them, the library of random 
peptides (linear dodeca- or loop-constrained heptapep-
tides in Ph.D.™-12 Phage Display Peptide Library or 
Ph.D.™-C7C Phage Display Peptide Library, respective-
ly) are fused to a minor coat protein pIII of the M13 
phage. After three rounds of panning several potentially 
positive clones (phage-displayed peptides) were selected 
for further analysis. First, they were subjected to Phage 
ELISA to verify their binding capacity with mAb6-9-1, 
then phage DNA was isolated and sequenced to reveal 
the predicted amino acid sequence of the mimotopes 
(polypeptides displayed on the surface of the phages). 
Phage clones selected from the Ph.D-12 Library were 
examined in three concentrations: 109, 108 and 107 pfu/
well, respectively. The absorbance value (OD450) two-
fold higher than the value of the negative control was 
considered positive. The first concentration (109 pfu/
well) was too high, since it resulted in positive signal for 
all selected clones. The lower concentrations allowed to 
select 7 clones having the highest reactivity among 21 
phages examined (Fig. 2). Six of them expressed the 
same peptide sequence, VHWDFRQWWQPS, while one 
different, FPSDWWSQAWSM.
Similar analyses were performed for phage clones se-
lected from the Ph.D-7C Library and resulted in selec-
tion of four mimotopes (ETDTLTQ, KTFLSSH, PHK-
PAMN and KPYTFVG) which occurred with the similar 
frequency.
The Pepitope server was used for epitope mapping 
using these affinity-selected peptides and the struc-
tural model of HA from the A/Swan/Poland/305-
135V08/2006 (H5N1). The combined algorithm (con-
sensus results of Mapitope and Pepsurf algorithms) se-
lected one cluster of four HA residues (W138, D140, 
F159 and W165) from 6 mimotopes that are shown on 
the structural model (Fig. 1c–d). The Pepitope analysis 
with only one, (FPSDWWSQAWSM) identified a larger 
cluster of 8 HA residues (K135, S136, W138, D140, 
A143, V147, S148 and W165) as an epitope. Both clus-
ters shared three residues (W138, D140 and W165). All 
of them were localized on the globular head of the HA1 
subunit in the proximity of the RBS. Moreover amino 
acids W138 and D140 were localized within the anti-
genic epitope called region A, while W165 in the region 
B. Antigenic epitopes (A–E) were proposed for H5N1 
Figure 1. Model of three-dimensional structure of HA from 
A/swan/Poland/305-135V08/2006 (H5N1) (a) and A/Viet-
nam/1194/2004 (H5N1) (b). 
Both proteins are represented as Connolly surface, colored by 
amino acids hydrophobicity based on Kyte-Doolittle scale (blue 
– hydrophilic, red – hydrophobic) (Kyte & Doolittle, 1982). (c) en-
larged head of HA from A/swan/Poland. Yellow surface represents 
the six amino acids building the RBS interface (Y107, W165, H195, 
E202, L206, and Y207), dark blue depicts the four residues of the 
mAb6-9-1 epitope (W138, D140, F159 and W165). W165 is shared 
between these two groups and is colored green. (d) ribbon dia-
gram of overlapped structures of the part of HA head from Poland 
(cyan color) and Vietnam (pink color). Two residues defining the 
binding specificity of mAb6-9-1 are marked on each structure, [1] 
D140 (Poland)/S (Vietnam), [2] S145 (Poland)/L (Vietnam).
Figure 2. Reactivity of individual phage clones with mAb6-9-1 in 
Phage ELISA. 
Plates were coated with mAb6-9-1 or BSA and to each well 108 
pfu and 107 pfu were added, plates were read at 450 nm. For 
each phage clone signal obtained with target protein (mAb6-9-
1) was compared with that obtained without target protein (e.g. 
BSA); presented on the horizontal axis OD value is reduced by the 
background (OD value for BSA). For the positive phage clones the 
amino acid sequences of the dodecapeptides are provided.
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highly pathogenic avian influenza viruses based on the 
classification of the antigenic domains of H3 (from 
H3N2 virus) (Peng et al., 2014). Both epitopes, A and B, 
contrary to the epitopes C–E, contribute strongly to the 
antigenic variation of the HPAI (highly pathogenic avian 
influenza) H5N1 viruses (Peng et al., 2014).
The conclusions from epitope mapping were verified 
by both, the Hemagglutination Inhibition test and ELI-
SA assay. In the HI test ability of mAb6-9-1 to inhibit 
binding of H5N1 (by RBS) to receptors on erythrocytes 
surface were analyzed. The HI titer was moderately posi-
tive, equal to 32, for the homologous virus, A/Turkey/
Poland/35/2007(H5N1), while for a nonhomologous vi-
rus A/chicken/Belgium/150/1999(H5N2) (DG Deven-
ter, Netherlands) it reached only 8, which was consid-
ered as negative. The HI results suggest that the epitope 
recognized by mAb6-9-1 might be localized nearby the 
RBS. Similarity between both antigens used in HI test 
was 86%, besides HA cleavage sites the differences were 
localized around RBS and the mapped epitope (aa posi-
tions: 135, 140, 154, 100, 124, 129, 140, 142, 154, 170, 
172, 184, 205, Fig. 3) which may explain the low HI titer 
obtained for the nonhomologous antigen.
With ELISA assay we analyzed binding of mAb6-9-1 
to various HA antigens from different clades of H5N1 
viruses as well as H1, H3 and H7 HA from several se-
lected strains (Fig. 4a). The results showed that mAb6-
9-1 can recognize both, a short (HA/Nde) and a long 
(OET) variants of H5 HA from A/swan/Poland/305-
135V08/2006 (H5N1), clade 2.2 as well as H5 HA from 
A/Bar-headed Goose/Qinghai/12/05 (H5N1), clade 2.2 
and H5 HA from A/Anhui/1/2005 (H5N1), but not the 
H5 HA from A/Hubei/1/2010 (H5N1), clade 2.3.2.1, 
A/Cambodia/R0405050/2007 (H5N1), clade 1 nor A/
Turkey/Germany- MV/R2472/2014 (H5N8). The data 
is in concordance with observation that the most vari-
able inter-clade positions are largely located on the glob-
ular head proximal to the RBS (Velkov et al., 2013). We 
also found that mAb6-9-1 does not recognize the H3 
HA from A/Wuhan/359/95 (H3N2), the H1 HA from 
A/New Caledonia/20/99 (H1N1) nor the H7 HA from 
A/chicken/Netherlands/1/03 (H7N7) (Fig. 4a).
Reactivity with HA/Nde antigen containing only the 
HA1 part of H5 HA confirmed that the epitope rec-
ognized by mAb6-9-1is located within HA1 subunit 
(Fig. 4b). Moreover, ELISA confirmed that mAb6-9-1 
binds probably a conformational epitope because dena-
turation of the antigens (reduction of disulfide bonds 
with 10 mM DTT) resulted in a complete loss of mAb6-
9-1 binding (Fig. 4b).
Comparison of the 3D structures of H5 HA proteins 
from A/swan/Poland/305-135V08/2006 (H5N1) and 
from A/Vietnam/1194/2004 (H5N1) (Fig. 1a, b and d) 
and an alignment of amino acid sequences of the H5 
HA antigens tested by ELISA and in HI tests (Fig. 3) 
clearly showed that two amino acids, D140 and S145 
in the proximity of the predicted epitope might decide 
about antigen binding specificity of mAb6-9-1. None of 
the analyzed HA proteins with the residue other than as-
partic acid in the position [1] i.e. D140 and other than 
serine in the position [2] i.e. S145 was recognized by 
mAb6-9-1.
Construction and expression of the scFv – mAb6-9-1 
derivative
The cDNA fragments encoding variable regions of 
heavy and light chains of mAb6-9-1 were cloned into 
the pGEM Teasy vector and sequenced. Each of four 
selected clones of VH carried the same (functional) se-
quence. Similarly, one functional sequence was found 
among thirty analyzed clones carrying VL, however, ma-
jority of them were classified as nonfunctional due to 
an internal stop codon in CDR3. Taking into account 
the nature of hybridoma cells such finding is not sur-
prising and was reported previously (Toleikis & Frenzel, 
2012). The predicted amino acid sequences of the CDRs 
in both variable chains are shown in Table 1. Sequenc-
es encoding VL and VH were assembled in two possi-
ble orientations (VL-VH and VH-VL) with the flexible 
linker (Gly4Ser)3 into scFv and cloned into the modi-
fied pET201vector downstream the sequence encoding 
thioredoxin (Supplementary file Fig. S1 at www.actabp.
pl). The choice of thioredoxin as the fusion partner was 
based on the literature data indicating that the formation 
of disulfide was essential for many scFvs described (Ju-
rado et al., 2006; Sonoda et al., 2010).
Finally, two recombinant variants of scFv in fusion 
with thioredoxin (TscFv: TVHVL and TVLVH) were 
Table 1 The sequences of complementarity determining regions (CDRs) of scFv6-9-1.
CDR1 CDR2 CDR3
Light chain
Heavy chain
SSVNY
GYSITSDYA
YTS
ISYSGST
QQFTSSPWT
ARSGISYYFGTDY
Amino acids complementarity which determines CDRs of the VH and VL domains were estimated according to the international ImMunoGeneTics 
information system® (IMGT, http://www.imgt.org)
Figure 3. Alignment of the fragments of HA antigens in the region adjacent to the mapped epitope of mAb6-9-1. 
The residues corresponding to those forming the RBS according to (Al-Majhdi, 2007) and those identified by the Pepitope software 
(W138, D140, F159, W165) as the potential target of mAb6-9-1 are marked above the alignment by asterisks and triangles, respectively. 
The positions that seem to define binding specificity of mAb6-9-1 are marked as white letters on a black background and additionally 
identified as [1] and [2] below the alignment. Belgium (H5N2) was used only in HI test. For the full names of the viruses refer to the text.
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Figure 4. Reactivity of mAb6-9-1. 
(a) Indirect ELISA with HA antigens in the native form. (b) Indirect ELISA with the selected HA antigens in the native and the reduced 
forms. C(-), negative control. The plates were coated with 300 ng of HA from the indicated viruses. Purified mAb6-9-1 and the anti-
mouse IgG conjugated to HRP were used as primary and secondary antibody. The full names of the viruses are provided in the text.
Figure 5. Verification of antigenic specificity of scFv. 
(a) Indirect ELISA using TscFv. The plates were coated with 300 ng of the indicated HA antigens or BSA as a negative control, recom-
binant TscFv (TVHVL, TVLVH) were used as primary antibody, while anti-strep IgG served as secondary antibody. (b) Phage ELISA using 
phage displayed scFv (PhscFv). Plates were coated with 500 ng of the indicated antigens, incubated with phages (PhVLVH or the nega-
tive control) and with anti-M13 IgG as secondary antibody. (c) and (d) sandwich ELISA using TVHVL and TVLVH, respectively. The plates 
were coated with 500 ng of TVHVL or TVLVH, incubated with the indicated HA antigens (250-31 ng/well) or BSA (c-), negative control, 
next incubated with anti-H5 HA polyclonal chicken IgY and with anti-chicken IgG-HRP. (e) sandwich ELISA using TVLVH. The plates were 
coated with 500 ng/well of TVLVH, concentrations of HA antigens and dilutions of anti-H5 HA polyclonal chicken IgY were as indicated. 
C1(-), C2(-) and C3(-) various negative controls: ELISA performed without HA antigen, without IgY 745, and without antigen and IgY745, 
respectively.
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produced in E. coli and purified on Ni-TDA agarose. 
SDS-PAGE analysis indicated the high purity of TscFvs 
obtained and their expected molecular weights to be 
about 42 kDa (Supplementary file Fig. S1b at www.act-
abp.pl).
Antigen binding specificity of the recombinant  
scFv 6-9-1
Irrespectively of the TscFv variant, in the indi-
rect ELISA the strongest binding was observed with 
HA/Nde – short H5 HA (17-340aa) from A/swan/
Poland/305-135V08/2006 (H5N1) (Fig. 5a). Surprisingly, 
the TscFv failed to recognize H5 HA from A/Bar-head-
ed Goose/Qinghai/12/05 (H5N1), the protein previous-
ly very well recognized by mAb6-9-1 (Fig. 4a and 5a). 
Higher plasticity of scFvs in comparison to the full-
size antibodies may affect their specificity and affinity 
(Shepelyakovskaya et al., 2011). To verify if this change 
of specificity was due to incorrect scFv folding a phage 
displayed variant of scFv (PhVLVH) was obtained. Pub-
lished data showed that the conversion of scFv from 
phage-bound to soluble form may results in change of 
specificity because the phage pIII protein may provide 
structural support for antigen- binding site (Kaku et al., 
2012). The results of phage ELISA (Fig. 5b) showed that 
indeed PhVLVH was able to specifically recognize the 
HA antigen from A/Bar-headed Goose/Qinghai/12/05 
(H5N1). These results strongly support the conclusion 
that the cloned cDNA encoding the variable regions of 
heavy and light chains correspond to the heavy and light 
chains of mAb6-9-1. Moreover, comparison of the ami-
no acids sequences determined by mass spectroscopy of 
trypsin-digested mAb6-9-1 with CDRs sequences of VH 
and VL predicted from nucleotide sequences of cloned 
scFv showed 87% and 100% identity, respectively (Sup-
plementary file Fig. S2). The alteration of antigen speci-
ficity observed by indirect ELISA prompted us to search 
for a better method of testing the activity of TscFv.
We performed sandwich ELISA using TscFvs (TVH-
VL and TVLVH, 500ng/well) as capture antibodies, an-
ti-H5 HA IgY 745 as detection antibody and various HA 
antigens. TscFvs were capable of targeting not only the 
short fragment of H5 HA (HA/Nde) but also the long 
fragment of H5 HA from A/Bar-headed Goose/Qing-
hai/12/05 (H5N1) (Fig. 5c–d).
The H5 HA from A/Anhui/1/2005 (H5N1; clade 
2.3.4) was also weakly recognized by TscFv, while bind-
ing to H5 HA from A/Vietnam/1203/2004 (H5N1; 
clade 1) and to H7 HA from A/chicken/Nether-
lands/1/03 (H7N7) was not detected (Fig. 5c–d). Ob-
tained results showed that binding capacity of TscFv to 
the long H5 HA version may be stronger than to the 
short H5 HA (HA/Nde) (Fig. 5c–d). This observation 
was confirmed in detailed analysis when serial two fold 
dilutions of both HA antigens in the range of 250–30 
ng/well and anti-H5 HA IgY (1:4 000–1:16 000) were 
applied (Fig. 5e). All data from sandwich ELISA were 
in accordance with the results obtained for mAb6-9-1 
(Fig. 4a).
The observed discrepancies of reactivity of TscFv to-
ward the long version of H5 HA, in two kinds of ELI-
SA, indirect and sandwich (Fig. 5a and 5c, d, e), may 
be explained by technical inconsistencies. The lack of 
binding to the long antigen was observed in the indirect 
assay, when HA antigens were used to coat the plates 
and the TscFv bound to the HA antigen was detected 
by the anti-Strep antibody. However, the binding with 
the same antigen was observed in the sandwich ELISA, 
when TscFv was used to coat the plates and HA an-
tigens bound to TscFv were recognized by the specific 
polyclonal anti-HA IgY antibody, detected subsequently 
by secondary anti-chicken IgY antibody conjugated with 
HRP. Due to the high plasticity of scFv, in the indirect 
ELISA, the Strep-tag was probably hidden in the confor-
mational structure of TscFv and was not accessible for 
the anti-Strep antibody.
In conclusion, epitope recognized by the full-length 
monoclonal antibody was mapped in the proximity of 
the RBS. This assumption is supported by the results of 
HI assay. Unfortunately, contrary to mAb6-9-1, TscFv 
did not demonstrate HI activity (not shown). However, 
such result does not exclude that scFv recognized the 
same epitope as mAb. To prevent hemagglutination, an-
tibody must bind to or near RBS and cause steric hin-
drance (Ascione et al., 2009; Zhang et al., 2013). It is 
more likely that the reduced size of scFv is not an effec-
tive barrier between virus and the red cell. Both antibod-
ies display narrow specificity to H5 HA from H5N1 in-
fluenza viruses, mostly from clade 2.2 and might be used 
effectively in immunosensors specifically detecting these 
type of viruses (Jarocka et al., 2014; Jarocka et al., 2016).
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